New Therapeutic Approaches for Acute Respiratory Distress Syndrome (ARDS)

Dear Colleagues,

Acute respiratory distress syndrome (ARDS) is a life-threatening heterogenous syndrome with many etiologies. The mortality rate of ARDS is really high at around 40%. Over the last few months, many patients have suffered a severe acute respiratory syndrome associated to the coronavirus 2 (SARS-CoV-2). Despite many years of experimental studies and advances in the treatment of ARDS, there is no definitive therapy; no pharmacological approach has proven to be beneficial. To date, the translation of bench-side findings into pharmacological effective therapies to use in the clinics has been elusive.

Here, we want to recruit manuscripts focused on recent developments in the treatment of ARDS. Further, we want to include new alternative and novel therapies tested in preclinical studies and new techniques and approaches to seek for therapies. We will explore some new pharmacological therapies and phase 1 and 2 ongoing studies. We would also like to highlight new biological treatments and recent innovative preclinical studies using new-discovered-molecules. Moreover, we will discuss the underlying molecular mechanisms for ARDS that are still not well understood.

 This Special Issue on “New Therapeutical Approaches for Acute Respiratory Distress Syndrome (ARDS)” aims to bring together clinicians and basic researchers, all of them international experts on the topic, to provide a deep overview on the topic. We will release a comprehensive view of recent advances for treating ARDS. Both original research articles and reviews are acceptable. Articles with mechanistic and functional insights at a cellular or molecular level, as well as animal models of disease, are particularly welcome.

Dr. Raquel Guillamat-Prats
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• acute lung injury/acute respiratory distress syndrome (ALI/ARDS)
• pharmacological approach
• immunomodulation
• cell therapy
• microRNA (miRNAs)
• immune system
• antibiotics
• inflammation
• preclinical studies
• translational research